Centogene NV (Centogene NV) Common Stock : $3.70 Mil (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Common Stock?

Centogene NV's quarterly common stock increased from Jun. 2022 ($3.44 Mil) to Dec. 2022 ($3.50 Mil) and increased from Dec. 2022 ($3.50 Mil) to Jun. 2023 ($3.70 Mil).

Centogene NV's annual common stock declined from Dec. 2020 ($3.23 Mil) to Dec. 2021 ($3.06 Mil) but then increased from Dec. 2021 ($3.06 Mil) to Dec. 2022 ($3.50 Mil).

Centogene NV Common Stock Historical Data

The historical data trend for Centogene NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Common Stock Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

2.17

2.65

3.23

3.06

3.50

Centogene NV Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															3.06	3.58	3.44	3.50	3.70

Centogene NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Centogene NV (Centogene NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.